1 duplicate copy in the archive
Title Match
Case Filed-30266House OversightCannabis Investment Report Highlights FDA Approval Prospects and Price Trends
November 11, 20251p
Case File
d-30266House OversightCannabis Investment Report Highlights FDA Approval Prospects and Price Trends
Other
The passage provides market data and regulatory updates on cannabis-derived pharmaceuticals and price trends, but lacks specific allegations, financial flows, or connections to high‑profile officials. FDA may approve the first cannabis‑derived drug (Epidiolex) in 2018. GW Pharmaceuticals submitted an NDA for Epidiolex in October 2017. Sativex is approved in the UK and other countries but not in th
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024646
Pages
1
Persons
0
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.